Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 87c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 4, 2021 4:06 PM EDT To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide
In the third quarter, well over 50,000 doses delivered and $102.4M of sotrovimab collaboration revenue recognized
Anticipated fourth quarter milestones include: topline sotrovimab intramuscular administration data, new hepatitis B data at AASLD and initial HIV vaccine immunology data
SAN FRANCISCO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.
The third quarter was both rewarding and... More
